KRYS · Krystal Biotech, Inc. · Documents

Apr 7

Proxy statement DEF 14A Meeting May 20, 2022

Proxy statement

Apr 7

Proxy statement DEFA14A

Proxy statement

Mar 28

Current report 8-K Events of Mar 26

Regulation FD disclosure

Mar 22

Current report 8-K

Regulation FD disclosure

Mar 15

Current report 8-K

Regulation FD disclosure

Feb 28

Current report 8-K Events of Feb 25

Financial results, Director or officer change, or executive pay

Feb 28

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Net loss $69.57M Diluted EPS -$3.13

Jan 18

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Dec 3

Current report 8-K Events of Nov 30

Entered into a material agreement

Nov 29

Current report 8-K

Regulation FD disclosure, Other events

Nov 8

Current report 8-K

Financial results

Nov 8

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Net loss $15.59M Diluted EPS -$0.70

Sep 16

Current report 8-K Events of Sep 13

Entered into a material agreement

Aug 19

Current report 8-K/A Events of Mar 24

Regulation FD disclosure

Aug 9

Current report 8-K

Financial results, Regulation FD disclosure

Aug 9

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Net loss $16.36M Diluted EPS -$0.74

Aug 2

Current report 8-K

Regulation FD disclosure

Jul 7

Current report 8-K Events of Jun 30

Entered into a material agreement

Jul 1

Current report 8-K

Regulation FD disclosure

May 24

Current report 8-K Events of May 21

Shareholder vote results

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Net loss $15.81M

Apr 6

Proxy statement DEF 14A Meeting May 21, 2021

Proxy statement

Apr 6

Proxy statement DEFA14A

Proxy statement

Mar 24

Current report 8-K

Regulation FD disclosure

Mar 1

Current report 8-K

Financial results

Mar 1

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Net loss $32.17M

Feb 5

Current report 8-K Events of Feb 2

Entered into a material agreement

Feb 2

Current report 8-K Events of Jan 29

Entered into a material agreement, Financial results

Jan 7

Current report 8-K

Regulation FD disclosure

Jan 4

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Dec 31

Current report 8-K

Entered into a material agreement

Nov 9

Current report 8-K

Financial results, Regulation FD disclosure

Nov 9

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Net loss $9.61M

Oct 1

Current report 8-K

Regulation FD disclosure

Aug 10

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2020 Q2, ended Jun 30

Quarterly report for FY2020 Q2

Net loss $6.83M

Jun 1

Current report 8-K Events of May 29

Shareholder vote results

May 21

Current report 8-K Events of May 18

Entered into a material agreement

May 14

Current report 8-K

Regulation FD disclosure

May 13

Current report 8-K Events of May 12

Other events

May 8

Proxy statement DEFA14A

Proxy statement

May 5

Current report 8-K Events of Apr 29

Director or officer change, or executive pay

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2020 Q1, ended Mar 31

Quarterly report for FY2020 Q1

Net loss $5.34M

May 4

Registration statement S-3ASR

Registration statement

Apr 13

Proxy statement DEF 14A Meeting May 29, 2020

Proxy statement

Mar 10

Current report 8-K

Financial results

Mar 10

Annual report 10-K FY2019, ended Dec 31

Annual report for FY2019

Net loss $19.09M

Feb 25

Current report 8-K

Director or officer change, or executive pay